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Available online 29 February 2008Human serum albumin binds ligands such as fatty acids and metals in circulation. Oxidative stress can modify
albumin and affect ligand binding. This study examines the role of oxidative stress and fatty acids in modulating
cobalt binding to albumin in patients with fatty liver. Elevated levels of malondialdehyde and protein carbonyls,
indicative of oxidative stresswere evident in serumof patientswith fatty liver. A signiﬁcant decrease in albumin–
cobalt binding was also observed. Albumin isolated from patient serum also showed an increase in bound fatty
acids. In vitro experiments indicated that while oxidant exposure or removal of fatty acids independently
decreased cobalt binding to albumin, removal of fatty acids from the protein prior to oxidant exposure did not
inﬂuence the oxidant effect on albumin–cobalt binding. These results suggest that oxidative stress and fatty acids
on albumin can inﬂuence albumin–cobalt binding in patients with fatty liver by independent mechanisms.






Human serum albumin (HSA) is synthesized in the liver and is the
most abundant protein in blood. It has a single polypeptide chain of 585
amino acids (66,500 Da) with three domains — I, II and III [1]. Each
domain consists of two sub domainsA and B. The structure of albumin is
stabilized by 17 disulphide bridges with a free thiol group at cysteine 34
which is prone to be oxidized [2]. Apart from maintaining colloid os-
motic pressure, albumin also plays a role in transport of a number of
ligands including hormones, hemin, bilirubin and fatty acids, as well as
transition metals such as copper, cobalt, nickel, and cadmium [3,4].
Modiﬁcations on albumin have been demonstrated in numerous patho-
physiological conditions such as acute coronary syndrome [5] and ske-
letal muscle ischemia [6]. These modiﬁcations can affect the protein's
ability to bind ligands, as seen in chronic renal and liverdisease [7]. It has
been demonstrated that the binding of albumin to cobalt is compro-
mised in patients with myocardial infarction [8] and myocardial ische-
mia [4] and this forms the basis for the albumin–cobalt binding test
(ACB) a marker for myocardial ischemia [4].
The binding of metals to albumin has been well studied, and four
differentmetal binding sites are known; siteA, site B, theN-terminal and
cys-34 [9]. Among the metals, binding is best characterized for copper
and nickel [3,10], which bind to the three N-terminal amino acid resi-
duesAsp-Ala-His. Cobalt is transported in circulation byalbumin [3] and
earlier studies using N-terminal peptides of albumin indicated that the
metal bound to the N-terminal at the sequence Asp-Ala-His-Lys (DAHK)2282485; fax: +9104162282486.
cvellore.ac.in
l rights reserved.[4], similar to copper and nickel [3]. However, a recent study has de-
monstrated that cobalt also binds to sites A and B on the albumin
molecule [9].
Another important ligand for albumin is fatty acids and HSA is the
primary transporter for the delivery of fatty acids to tissues, having at
least seven binding sites for this ligand [11]. Oxidative stress is one of
the mechanisms by which modiﬁcation of albumin can occur [7], and
free radicals have been implicated in the etiology of liver disease,
playing a role in progression from fatty liver to ﬁbrosis and cirrhosis
[12,13]. Since albumin is synthesized in the liver, and oxidative stress
is known to be a feature of liver disease, we hypothesized that oxida-
tive stress during fatty liver disease can cause modiﬁcation on serum
albumin, which may inﬂuence ligand binding properties of the pro-
tein. We tested this hypothesis by studying serum from patients with
fatty liver and demonstrate that association of albumin with fatty
acids is altered in an oxidative milieu and this can inﬂuence the cobalt
binding capacity of the protein.
2. Methods
Tris (hydroxymethyl) aminomethane (Tris), puriﬁed human serum albumin (HSA),
bromo cresol green, dithiothreitol (DTT), 2,4 dinitro phenyl hydrazine (DNPH), 1,1,3,3
tetramethoxy propane, catalase, xanthine and xanthine oxidase were obtained from
Sigma Chemical Co., St Louis, MO, U.S.A. Cibachron Blue was from CIBA-GIEGY. All other
chemicals and solvents used were of analytical grade.
2.1. Patients and control subjects
The study included 28 patients who were diagnosed with fatty liver by radiological
ﬁndings, with high levels of alanine aminotransferase (ALT) and no history of alcohol
consumption, diabetesmellitus or hyperlipoproteinaemia. Controls were 28 patients with
irritable bowel syndrome and no liver involvement. The following blood investigations
were done in all subjects — aspartate aminotransferase (AST), alanine aminotransferase
Fig. 1. Protein carbonyl (A) and malondialdehyde (B) levels in serum from controls (□)
and patients with fatty liver (■). Experiments were carried out as described in the
Methods section. The data is expressed as mean±SEM, n=28. (⁎Pb0.05).
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triacylglycerol, HbsAg and anti-HCV. The studywas approved by the Institutional Research
Committee and samples were obtained after informed consent.
2.2. Oxidative stress parameters
Serum was used for the assessment of oxidative stress parameters. Protein car-
bonylation was determined spectrophotometrically based on the reaction of 2,4-dinitro-
phenylhydrazine with protein carbonyls [14] and the results were expressed as nmol
carbonyl content/ml of serum.Malondialdehyde, the endproductof lipid peroxidationwas
measured by the thiobarbituric acid method using 1,1,3,3 tetramethoxy propane as stan-
dard [15].
2.3. Assessment of cobalt binding to albumin
The serum samples were assessed for cobalt binding as described with slight modi-
ﬁcations [4]. Brieﬂy, serum samples were incubated with cobalt chloride 0.232 mM (ﬁnal
concentration) andmade up to 100 µlwith phosphate buffer saline (PBS pH7.4) inwells of
amicrotiter plate. Thiswas incubated for 10min to allow the cobalt to bind to the albumin.
At theendof the incubation, theunboundcobaltwasmeasuredby reducing cobalt chloride
with 1.6mMDTT (ﬁnal concentration), adding 200 µl of saline and reading the absorbance
at 490 nm. Absorbance readings were also measured in parallel wells, where only cobalt
chlorideandDTTwerepresent,without serum. Theamountof boundcobaltwas calculated
from subtracting the value for unbound cobalt from that of thewellswhich had only cobalt
and DTT without serum.
2.4. Separation of albumin from serum
For separation of albumin from serum,100 µl serumwas incubatedwith 250 µl of blue
sepharose beads (Cibachron Blue) in Tris HCl buffer (0.05 M pH 8) for 30 min, following
which the beads were separated by centrifugation at 4000 rpm for 10 min. These beads
were then washed with Tris HCl buffer, following which the bound albumin was eluted
with 100 µl of Tris HCl (0.05 M)/NaSCN (0.2 M).
2.5. In vitro oxidant exposure
For examining the direct effect of oxidative stress on cobalt binding, normal serum
(2.5 g/dL) as well as puriﬁed human serum albumin (2.5 g/dL) was treated with either
hydrogenperoxide (200 µM) and copper sulphate (CuSO4) (200 µM), or xanthine (1mM) and
xanthine oxidase (100 mU) for 30 min at 37 °C. Following treatment, the cobalt binding
capacitywas estimated asmentioned above. To conﬁrm roles, if any, of hydrogenperoxide or
superoxide in these changes, experiments were also carried out in the presence and absence
of catalase (1000U) or superoxidedismutase (SOD) (1000U) respectively. To evaluate the role
of hydroxyl radicals in the process, experiments were done with and without thiourea
(50 mM) and mannitol (50 mM), which have been used to scavenge hydroxyl radicals [16].
2.6. Lipid analysis from albumin
Total lipids were extracted from albumin as described [17]. The lower organic phase
was concentrated using nitrogen, resuspended in a small volume of chloroform/methanol
(2:1) and used for lipid analysis. Neutral lipids were separated by thin layer chro-
matography (TLC) on silica gel G plates using the solvent system of hexane/diethyl ether/
acetic acid (80:20:1, by vol). Spots corresponding to standard fatty acids run in parallel
were identiﬁedby iodineexposure andeluted. Theeluted fattyacidsweremethylatedwith
methanol and concentrated HCl for 4 h at 70 °C, following which the fatty acid methyl
esters were extracted with 1 ml of heptane. Individual fatty acid content was then quan-
titated using gas chromatography as described [18].
2.7. Removal of fatty acid from puriﬁed HSA
Albumin (5.0 g/dL) wasmixed with activated charcoal (2.5 g) and the pH of the solution
was lowered to 3.0 by the addition of 0.2 N HCl. The solutionwas then placed in an ice bathTable 1
Characteristics of controls and patients with fatty liver included in the study
Parameter Controls Fatty liver
Gender (M/F) 19/9 20/8
Age (year) 41.17±9.55 41.32±8.75
BMI (kg/m2) 20.03±3.0 25.20±4.0
Cholesterol (mg/dL) 165.25±42.6 185.84±43.8
TAG (mg/dL) 144.9±73.1 232.08±130.65
AST (IU/L) 32.38±13.39 45.33±20.66
ALT (IU/L) 33.65±19.76 77.55±57.56
ALP (IU/L) 90.07±26.65 111.59±35.48
Albumin (g/dL) 4.37±0.31 4.47±0.38
Total protein (g/dL) 7.6±0.54 7.6±0.54
Total bilirubin (mg/dL) 0.66±0.34 0.74±0.41andmixed for 1 h, followingwhich the charcoal was removed by centrifugation at 3000 rpm
and the solutionpHadjustedback to7.0 byadditionof 0.2NNaOH.Control experimentswere
carried out to conﬁrm that changes in pH did not inﬂuence the cobalt binding assay.
2.8. Estimation of albumin
Albumin content was measured using the bromocresol green (BCG) method [19].
2.9. Statistical analysis
Results are expressed asmean±S.E.M. Statistical calculationswere performedusing SPSS
software for windows (version 9.0). Mann–Whitney and Student's t test were performed for
statistical analysis. A P value of less than 0.05 was taken to indicate statistical signiﬁcance.
3. Results
Patients with fatty liver on ultrasound, who were recruited for the
study, had a signiﬁcantly higher BMIwhen compared to controls (Table 1).
Serum levels of alanine transaminase were also signiﬁcantly higher
in patients when compared to controls, as were serum triglyceride
levels. No difference in levels of gamma-glutamyltransferase wasFig. 2. Cobalt binding capacity of albumin in serum from controls (□) and patients with
fatty liver (■). Experiments were carried out as described in the Methods section. The
data is expressed as mean±SEM, n=28. (⁎Pb0.05).
Fig. 4. Cobalt binding capacity of puriﬁed albumin exposed toxanthine/xanthine oxidase
in the presence or absence of superoxide dismutase, catalase and CuSo4 as indicated
(A) or H2O2, CuSo4, catalase, thiourea and mannitol as indicated (B). Experiments were
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there was no signiﬁcant difference in levels of serum albumin bet-
ween patients and controls.
Initial experiments were then carried out to evaluate oxidative
stress in serum from patients with fatty liver and the results are
shown in Fig. 1. Total protein oxidation assessed by protein carbonyls
was signiﬁcantly increased (Pb0.05) in serum of patients with fatty
liver (Fig. 1A). This was accompanied by a signiﬁcant increase in
malondialdehyde (Pb0.05) (Fig. 1B) compared to control subjects.
Since albumin is the predominant protein in serum and has been
shown to be susceptible to oxidative modiﬁcation, it is possible that
the increase in protein carbonyl content could reﬂect modiﬁcation on
the protein. To determine if oxidative stress in serum had any func-
tional signiﬁcance on albumin, we investigated the cobalt binding
capacity of serum albumin in patients with fatty liver. As seen in Fig. 2,
a slight but signiﬁcant decrease in cobalt binding was seen in serum
from patients with fatty liver, when compared to controls.
To determine whether oxidative stress could have an effect on
albumin–cobalt binding, in vitro studies were then carried out using
normal serum as well as puriﬁed human serum albumin. Exposure to
hydrogen peroxide and copper sulfate resulted in a decrease in cobalt
binding capacity of albumin on pure HSA (Fig. 3A). Hydrogen peroxide
alone had no effect, while copper sulfate alone showed a slight
decrease which was not statistically signiﬁcant. A similar result was
obtained in serum as well (Fig. 3B) where the decrease was prevented
by the presence of catalase (Fig. 3B), conﬁrming the role of hydrogen
peroxide in the process.
Experiments were also conducted using other physiologically
relevant oxidant generating systems such as the xanthine/xanthine oxi-
dase system, which generates superoxide radicals. Surprisingly cobalt
binding to albuminwas not altered in the presence of xanthine/xanthineFig. 3. Cobalt binding capacityof puriﬁedalbumin (A) andnormal serum(B) afterexposure
to H2O2 and CuSo4 in the presence and absence of catalase. Experiments were carried out
as described in the Methods section. The data is expressed as mean±SEM, n=6. ⁎Pb0.05
when compared to pure HSA, #Pb0.05 when compared to control serum, and †Pb0.05
when compared to CuSo4 and H2O2.
carried out as described in the Methods section. The data is expressed as mean±SEM,
n=4. ⁎Pb0.05 when compared to pure HSA, #Pb0.05 when compared to CuSo4 and
H2O2, and †Pb0.05 when compared to CuSo4 and H2O2.oxidase (Fig. 4A). This suggests that the superoxide anion per se does not
inﬂuence albumin–cobalt binding. However, the superoxide anion can
be converted to hydrogenperoxide by superoxide dismutase. To conﬁrm
the results with direct hydrogen peroxide exposure, experiments
were repeated with the xanthine/xanthine oxidase system in the pre-
sence of superoxide dismutase, with and without copper sulfate. Cor-
roborating the results from Fig. 3, incubation with xanthine/xanthine
oxidase+superoxide dismutase, which would produce hydrogen per-
oxide alone, had no effect on albumin–cobalt binding (Fig. 4A). However,
inclusion of copper sulfate resulted in a signiﬁcant decrease in albumin–
cobalt binding, an effect which was reversed by addition of catalase
(Fig. 4A). All these data suggest that only hydroxyl radicals, produced by
the Fenton reaction when hydrogen peroxide and copper are present
could result in decreasing cobalt binding to albumin. To conﬁrm this,
experiments were repeated in the presence of thiourea and mannitol,
which can scavenge hydroxyl radicals [16]. As seen in Fig. 4B, the pre-
senceof thiourea andmannitolwas able to signiﬁcantly reverse the effect
of hydrogenperoxideand copperonalbumin–cobalt binding, conﬁrming
the role of the hydroxyl radical in the process.
Albumin in circulation also binds to fatty acids and patientswith fatty
liver have been shown to have increased serum levels of fatty acids [20].
To determine if the fatty acid content on albumin could inﬂuence the
protein's binding to cobalt, blue sepharose was used to extract serum
albumin from controls and fatty liver patients. The blue sepharose ex-
traction resulted in isolation of serumalbumin fromboth controls aswell
as fatty liver patients (data not shown). Fatty acid analysis from this
albumin indicated that levels of oleic, myristic and lauric acid were
increased in patients with fatty liver when compared to controls (Fig. 5).
These were the only fatty acids which were consistently detected as
beingassociatedwith albumin frompatientswith fatty liver andcontrols.
Fig. 6. Cobalt binding capacity of puriﬁed human serum albumin before (□) and after (■)
removal of fatty acid exposed to H2O2 and CuSo4 or both. The data is expressed as mean±
SEM, n=4. ⁎Pb0.05 when compared to pure HSA, #Pb0.05 when compared to pure HSA,
and †Pb0.05 when compared to defatted HSA.
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min? To examine this, in vitro experimentswere carried outwhere fatty
acidswere removed frompuriﬁed human serumalbumin and the cobalt
binding capacity of the samples analyzed. Fatty acid removal from
albuminwasconﬁrmedbyTLC (datanot shown). Interestingly, as seen in
Fig. 6, cobalt binding to albumin decreased in samples where fatty acid
had been removed, suggesting that fatty acid binding could inﬂuence
cobalt binding to albumin.
The results so far suggest that oxidative stress is present in serum
from patients with fatty liver, accompanied by a decrease in cobalt
binding to albumin. In vitro exposure to free radicals or removal of
fatty acids also decreases cobalt binding on albumin, suggesting that
patients with fatty liver may have decreased fatty acids bound on
albumin. Interestingly, however; analysis of albumin from patients
showed an increase in fatty acids bound to albumin. This indicates that
fatty acids may have a protective effect on maintaining albumin–
cobalt binding. However, would removal of fatty acids aggravate the
effect of oxidative stress on albumin–cobalt binding? This was tested
in vitro where puriﬁed human serum albumin was subjected to
oxidative stress subsequent to removal of fatty acids from the protein.
As seen in Fig. 6, removal of fatty acids did not exacerbate the decrease
in albumin–cobalt binding induced by oxidative stress, suggestingFig. 5. Fatty acid content on albumin from controls and patients with fatty liver. Levels of
oleic acid (A), myristic acid (B) and lauric acid (C) from albumin extracted from serum of
controls (□) and patients with fatty liver (■). Experiments were carried out as described
in the Methods section. The data is expressed as mean±SEM, n=5. (⁎Pb0.05).that oxidative stress and fatty acids inﬂuence albumin–cobalt binding
by separate mechanisms.
4. Discussion
Albumin, thepredominantprotein in circulation ismainlysynthesized
in the liver and binds to a number of ligands; serving as transport vehicle
for numerous endogenous compounds including bilirubin, hemin, heavy
metals and fatty acids [21]. The protein is known to be affected in con-
ditions such as exposure to cigarette smoke [22,23], diabetes and renal
diseases [24,25]. Structural alterations on human serum albumin have
been described in renal disease such as uremia and chronic liver disease
such as liver cirrhosis [7]. One of the causes ofmodiﬁcation on albumin is
oxidative stress [26] andoxidized albuminhas beendetected in the blood
of patients suffering fromdiabetes [24] andkidneydisease [25]. Oxidative
stress has also been demonstrated in conditions such as non alcoholic
fatty liver disease (NAFLD) [27] and non alcoholic steatohepatitis (NASH)
[28,29] conditions which can develop from fatty liver. It has been sug-
gested that albumin, being synthesized in the liver could be exposed to
free radicals, resulting in conformational changes which may affect its
binding property [7]. Our initial studies focused on oxidative markers in
serum frompatientswith fatty liver, and the increase inmalondialdehyde
and protein carbonyl indicates the presence of lipid peroxidation and
protein oxidation, suggestive of oxidative stress. But does this result in
functional alterations on serum albumin?
Altered cobalt binding to albumin has been reported in myocardial
infarction (MI) [8] myocardial ischemia [4] and acute coronary syn-
drome [5] and this has been used as a diagnostic test to determine
susceptibility to undergo MI [4]. However, it has also been shown that
reactive oxygen species such as superoxideandhydroxyl radicalsmodify
albumin during myocardial disease [26], suggesting a role for free radi-
cals in inducing change in cobalt binding. Our data indicates that oxi-
dative stress in serum of patients with fatty liver is accompanied by a
slight but signiﬁcant decrease in cobalt binding to albumin. But is
oxidative stress and change in cobalt binding linked, or are they two
unrelated observations? ROS generation in vitro has been shown to
produce structural changes in human albumin as well as synthetic N-
terminus tetra- and octa-peptides from themolecule, with loss of cobalt
binding capacity [30]. Our in vitro experiments produced similar results,
where exposure tohydrogenperoxide in thepresence of copper resulted
in a decrease in albumin–cobalt binding. The reversal of this effect with
catalase conﬁrms the role of H2O2 in mediating the effect. More spe-
ciﬁcally, this effect seems to be mediated by the hydroxyl radical, since
superoxide generated by the xanthine/xanthine oxidase system had no
effect and thiourea and mannitol were able to prevent the decrease in
albumin–cobalt binding. Thiourea and mannitol have been used as
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have been shown to be selectively susceptible to hydroxyl radicals in
comparison to the superoxide and hydroperoxyl radicals [31,32]. This
data is also in accordance with previous studies where simultaneous
presence of H2O2 and copper was required to alter cobalt binding of
albumin [26]. The experiments also suggest that copper does not inter-
ferewith cobalt binding, probably because they bind at different sites on
the protein [26].
The data so far indicates that oxidative stress in patients with fatty
liver results inmodiﬁcation of albumin, such that the protein's binding
to cobalt is altered. But what is the mechanism? Binding of transition
metals such as copper and nickel is proposed to occur at the N-
terminus of the albumin molecule at the amino acid sequence Asp-
Ala-His-Lys [3]. Earlier studies examining albumin–cobalt binding in
the context of cardiovascular disease have used peptides with the N-
terminal sequence and shown that it also binds cobalt and loss of the
sequence results in decreased cobalt binding [30]. This was suggested
as the mechanism for decreased cobalt binding in myocardial infarc-
tion [4]. However, cobalt may bind to additional sites on albumin [33]
and a recent study has demonstrated that the principle cobalt binding
site on HSA are sites A and B in the interior, with the N-terminal site
being of lesser importance [9]. A recent study by Bar-Or et al. using
plasma from controls and patients with myocardial ischemia indicates
that binding to N-terminal may not be the only mechanism for
albumin–cobalt binding [34].This indicates that alternate mechanisms
for the decrease in cobalt binding exist, involving other ligands bind-
ing in the interior of the molecule.
HSA is the primary transporter for the delivery of fatty acids (FA) to
tissues, the FA:HSA ratio being between 0.1:1 and 2:1 under physio-
logical conditions and rising to 6:1 or greater in peripheral vasculature
during fasting or exercise [35,36]. The binding of FA to HSA can also
increase in pathological conditions such as diabetes, liver disease and
cardiovascular disease [37]. At least seven binding sites for fatty acids
have been identiﬁed in albumin [11], saturated fatty acids binding
with increasing afﬁnity as their chain length increases [38]. As men-
tioned earlier, four different metal binding sites have been identiﬁed
in albumin [9] and it has been reported that fatty acids and cadmium
compete with each other to bind to site A on albumin [21]. According
to Mothes et al. cobalt binds to sites A and B on the albumin molecule
[9]. But can fatty acids on albumin modulate the protein's cobalt
binding activity? Our data shows that this seems to be the case, since
removal of fatty acids from HSA results in decreased cobalt binding to
the protein.
But what is the relationship between oxidative stress, fatty acids and
cobalt binding on albumin in the context of fatty liver disease? Based on
the data on oxidative stress and cobalt binding from patients, it seemed
that free radicals decrease albumin–cobalt binding, which agrees with
the in vitro oxidant exposure experiments. The role of fatty acids in the
context is a bit more complex. The in vitro experiments indicate that
fatty acid removal compromised cobalt binding; but patients with fatty
liver (who had decreased cobalt binding to albumin) showed signiﬁcant
increases in oleic, myristic and lauric acids bound to albumin. The
increase in fatty acids on albumin is probably expected, since patients
with fatty liver have increased levels of free fatty acids [20], where the
rate of FFA uptake is unregulated and therefore directly proportional to
plasma FFA concentrations [39]. Though palmitic acid and stearic acid
arepresent in serum, it has been shown thatbetweenbovineandhuman
serum albumin, palmitate binds more tightly to bovine whereas laurate
and oleate bind more tightly to human serum albumin [40,41]. This
could be the reason why we were unable to detect palmitate on the
albumin isolated from controls or patients. The data then suggests that
fatty acids have a protective effect in maintaining albumin–cobalt
binding, though the in vitro experiments suggest that mechanisms for
this protection are independent of oxidative modiﬁcation. The protec-
tion by increased albumin-fatty acid binding may also explain the rela-
tively small decrease in albumin–cobalt binding in patients with fattyliver. Since conditions such as cardiovascular disease are also associated
with increase in serum free fatty acids [42] and oxidative stress [43], it is
possible that this mechanism may hold true in cases of myocardial
infarction as well.
In conclusion, our studies demonstrate that oxidative stress in
serum of patients with fatty liver is associated with a decrease in
cobalt binding capacity of albumin. This is accompanied by an increase
in fatty acid binding on albumin in these patients, which probably
attenuates the effect of free radicals on cobalt binding to the protein.
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